By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bionor Pharma ASA 

6701 Democracy Boulevard
Suite 300
Bethesda  Maryland  20817  U.S.A.
Phone: 301-571-9493 Fax: 301-564-9619


SEARCH JOBS


Industry
Biotechnology






Company News
UPDATE: Bionor Pharma ASA Announces That The Combination Of Vacc-4x + Revlimid(R) Is Well Tolerated And Increases CD4 Counts In People Living With HIV 11/19/2014 12:55:12 PM
Bionor Pharma ASA Announces That The Combination Of Vacc-4x + Revlimid® Is Safe And Increases CD4 Counts In People Living With HIV 11/18/2014 1:22:08 PM
Bionor Pharma ASA's Phase II Vacc-4x Data Published In The Lancet Infectious Diseases 2/11/2014 9:32:10 AM
Bionor Pharma ASA Appoints Anker Lundemose New VP and CEO 1/29/2013 7:02:25 AM
Bionor Pharma ASA Release: Final Regulatory Approvals Received for International Study to Reboost Patients From the Completed Vacc-4x Phase II Trial 12/5/2012 9:37:03 AM
Bionor Pharma ASA Release: Analysis of Immune Responses in Patients Treated With Vacc-4x Supports Further Development 9/12/2012 10:05:37 AM
Bionor Pharma ASA Release: Study of Vacc-4x Combined With Celgene (CELG)'s Revlimid® (lenalidomide) in HIV Patients With Impaired Immune System Approved to Begin 8/13/2012 8:48:18 AM
Bionor Pharma ASA's Therapeutic HIV Vaccine Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting in Long-Term Reduction in Viral Load and Potential for Periodic "Boosts" That Could Result in New Treatment Option for People Living With HIV/AIDS 7/20/2012 9:18:04 AM
HIV- and Oncology Research Expert Professor Gus Dalgleish Joins Clinical Advisory Board Bionor Pharma ASA 7/17/2012 9:12:52 AM
GLOBVAC Awards Bionor Pharma ASA US $1.7 Million to Advance Research Towards an HIV Cure Using Vaccine Vacc-4x 7/9/2012 8:56:57 AM
1234
//-->